Short Telomeres Are Independent Prognostic Factors Associated with Poor Outcome in Chronic Lymphocytic Leukemia (CLL) Treated with Chlorambucil with or without the Addition of Rituximab or Obinutuzumab: Results from CLL11 Trial of the Gcllsg

Abstract

Abstract Telomeres are DNA repeats at the ends of the chromosomes that are important for maintaining genomic integrity by preventing erosion of the ends. Short telomeres in CLL have previously been shown to be associated with inferior prognosis however its prognostic relevance in chlorambucil based treatment has not been studied. Here, we evaluated associations and prognostic relevance of telomere length in CLL treated with chlorambucil (CLB), CLB+Rituximab(CLB+R) and CLB+Obinutuzumab (GA-101) (CLB+G) in the international, multicenter, randomized CLL11 trial. Telomere length was analyzed using a Q-PCR based method on a representative cohort of 700 patients (89.6%) with available DNA from CD19 enriched or unsorted PBMCs. The method was validated using terminal restriction fragment length analysis (TRF; R2=0.915). Telomere length in CLL11 patients was highly variable (2.2kb to 28.6kb) with a median telomere length of 4.2kb. Telomere length associations were studied by dichotomizing into short (≤median) and long (>median) telomere subgroups. Among the clinical parameters, telomere length showed no association with age, ECOG status, presence of B symptoms, CIRS score, and serum b2-microglobulin (b2-MG). However, short telomeres were significantly associated with male sex (P=0.010), Binet stage (P=0.001), serum thymidine kinase level (s-TK; P Regarding outcome, telomere length was associated with response to therapy in the CLB+R (P=0.001) and CLB+G (P=0.023) treatment arms, while no significant association was observed for the CLB group (P=0.275). Moreover, short telomeres were significantly associated with positive MRD in bone marrow (89.8% vs. 72.9%; P=0.018) and as a trend in peripheral blood (70.2% vs. 58.2%; P=0.068) for CLB+G treatment. At a median observation time of 41.6 months, there were 534 (76.3%) events for progression free survival (PFS) and 195 events (27.9%) for overall survival (OS). Telomere length showed a statistically significant association with PFS (P Multivariable analysis to identify independent prognostic factors was performed including variables significantly associated with PFS in univariate analysis such as treatment arms, Binet stage, b2-MG, s-TK, WBC count, presence of 17p- and/or TP53 mutation, 11q-, mutation status of IGHV and NOTCH1 and telomere length. Short telomeres (HR 1.307; 95%CI 1.054-1.622; P=0.015) along with the treatment arms CLB+R (P In summary, short telomere length in CLL was found to be associated with other adverse biological disease characteristics as well as treatment efficacy, as an independent prognostic factor for PFS and OS in the context of CLB based therapy. The study suggests the value to assess telomere length for risk stratification of CLL patients and to evaluate this marker in the context of novel treatment options targeting biological disease features. Download : Download high-res image (141KB) Download : Download full-size image Figure . Disclosures Bahlo: F. Hoffmann-LaRoche: Honoraria, Other: travel grants. Goede: Roche: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel grants, Speakers Bureau; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: travel grants, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees. Ritgen: BMS: Consultancy, Other: travel support; F. Hoffmann-LaRoche: Consultancy, Honoraria, Other: travel support, Research Funding; Gilead: Other: travel support; Pfizer: Consultancy. Fingerle-Rowson: F. Hoffmann-La Roche: Employment. Kneba: AbbVie: Consultancy, Honoraria, Other: travel support, Research Funding; F. Hoffmann-LaRoche: Consultancy, Honoraria, Other: travel support, Research Funding; Gilead: Consultancy, Honoraria, Other: travel support, Research Funding; Janssen-Cilag: Consultancy, Honoraria, Other: travel support, Research Funding; Mundipharma: Consultancy, Honoraria, Other: travel support, Research Funding. Fischer: Roche: Other: Travel Grants. Hallek: AbbVie: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; F. Hoffmann-LaRoche: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria, Research Funding; Janssen-Cilag: Consultancy, Honoraria, Research Funding; Mundipharma: Consultancy, Honoraria, Research Funding. Stilgenbauer: Pharmacyclics: Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Gilead: Consultancy, Honoraria, Research Funding; Sanofi: Consultancy, Honoraria, Research Funding; Mundipharma: Consultancy, Honoraria, Research Funding; Genentech: Consultancy, Honoraria, Research Funding; Hoffman La-Roche: Consultancy, Honoraria, Research Funding; GSK: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria, Research Funding; Celgene: Consultancy, Honoraria, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Genzyme: Consultancy, Honoraria, Research Funding; AbbVie: Consultancy, Honoraria, Research Funding; Boehringer-Ingelheim: Consultancy, Honoraria, Research Funding.